ABBV (AbbVie) GF Value : $157.02 (As of Mar. 26, 2025)

View and export this data going back to 2012. Start your Free Trial

What is AbbVie GF Value?

As of today (2025-03-26), AbbVie's share price is $201.34. AbbVie's GF Value is $157.02. Therefore, AbbVie's Price-to-GF-Value for today is 1.28. Based on the relationship between the current stock price and the GF Value, GuruFocus believes AbbVie is Modestly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

AbbVie (NYSE:ABBV) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

AbbVie's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	201.34	/	157.02
	=	1.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie GF Value Related Terms

Thank you for viewing the detailed overview of AbbVie's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV34:Brazil 4AB:Bulgaria ABBV:Austria ABBV:Argentina

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

https://www.abbvie.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Executives

Scott T Reents	officer: SVP, Chief Financial Officer	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee	officer: SVP, Controller	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Timothy J. Richmond	officer: EVP, Chief HR Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis	officer: EVP, GC and Secretary	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Richard A Gonzalez	officer: Chairman of the Board and CEO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Nicholas Donoghoe	officer: SVP, Enterprise Innovation	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart	officer: SVP, US Commercial Operations	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Robert A. Michael	officer: VP, Controller	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt	officer: SVP, Operations	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin	director	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis	director	1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Elaine K. Sorg	officer: Sr. V.P., U.S. Commercial Ops.	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom	officer: SVP & Pres Global Allerg Aesth	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin	director	200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Michael Severino	officer: EVP, R&D and CSO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064